Clinical trial
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478
Study timeline
Study start (actual)2024-02-26Date precision: day
Registry last updated2026-10-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Solid Tumorunresolved
Melanomaunresolved
Head and Neck Cancerunresolved
Gastric Cancerunresolved
Ovarian Carcinomaunresolved
Cervical Cancerunresolved
Endometrial Cancerunresolved
Bladder Cancerunresolved
Esophageal Cancerunresolved
Pancreatic Carcinomaunresolved
Prostate Cancerunresolved
Non-small Cell Lung Cancer (NSCLC)unresolved
Lung Cancerunresolved
Breast Cancerunresolved
Interventions
HER3-DXdDRUG
Sponsors & collaborators
Daiichi Sankyolead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06172478 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.